Change of Name

Recorded: 2011-10-06 Received: 2011-10-06 Pages: 4

Assignor

EURAND, INCORPORATED

Executed: 2011-07-12

Assignee

APTALIS PHARMATECH, INC.

845 CENTER DRIVE, VANDALIA, OH, 45377, UNITED STATES

Covered Properties (18)

Orally Disintegrating Tablet Compositions of Temazepam

Application: 12/339,908 →

Pulsatile release histamine H2 antagonist dosage form

Application: 12/216,881 →

Pharmaceutical Compositions Comprising an Active Substance from the Substituted Benzhydrylpiperazine Family

Application: 12/057,177 →

Orally disintegrating Tablet Compositions of Temazepam

Application: 61/015,931 →

Orally Disintegrating Tablets Comprising Diphenhydramine

Application: 61/012,531 →

Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids

Application: 11/668,408 →

Drug Delivery Systems Comprising Weakly Basic Selective Serotonin 5-HT3 Blocking Agent and Organic Acids

Application: 11/668,167 →

Timed, Sustained Release Systems for Propranolol

Application: 11/500,892 →

Taste-Masked Pharmaceutical Compositions with Gastrosoluble Pore-Formers

Application: 11/256,653 →

Taste-Masked Pharmaceutical Compositions

Application: 11/248,596 →

Orally disintegrating tablets of atomoxetine

Application: 11/223,819 →

Timed, pulsatile release systems

Application: 11/120,139 →

Pulsatile release histamine H2 antagonist dosage form

Application: 10/875,627 →

Extended release systems for macrolide antibiotics

Application: 10/658,078 →

Timed, sustained release systems for propranolol

Application: 10/453,848 →

Extended Release Dosage Forms of Propranolol Hydrochloride

Application: 10/335,295 →

Timed, sustained release systems for propranolol

Application: 10/334,052 →

Pharmaceutical compositions containing indistinguishable drug components

Application: 10/310,357 →